Clinical Trial: A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07669051) titled 'A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment' on June 02.

Brief Summary: This is a prospective, single-center, Phase II clinical study designed to explore the efficacy and safety of ivonescimab plus third-generation EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer who developed slow progression or potential progression after prior EGFR-TKI therapy.

Study Start Date: Jan. 01

Study Type: INTERVENTIONAL

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)

Intervention: DRUG...